ClinicalTrials.Veeva

Menu

Efficacy of a Fibrin Sealant in Burn Surgery

Mass General Brigham logo

Mass General Brigham

Status

Completed

Conditions

Burns

Treatments

Drug: Tisseel Fibrin Sealant

Study type

Interventional

Funder types

Other

Identifiers

NCT00181974
Not sponsored

Details and patient eligibility

About

The purpose of this study is to determine the effectiveness of a fibrin glue in burn surgery with respect to hemostasis and skin graft fixation.

Full description

Burn patients require extensive split-thickness skin grafting operations. These operations necessitate excision of burn wounds and the procurement of autografts. Both of these result in bleeding open wounds. Fibrin sealants may be of benefit in three aspects of burn surgery:

  1. as a hemostatic agent on excised burns,
  2. as a hemostatic agent on donor sites, and
  3. as a method of fixation of skin grafts to wounds.

Skin grafts are routinely secured with surgical staples. Patients with large burns will commonly have hundreds, even thousands of staples used during the course of their care. Problems associated with the use of surgical staples include:

  1. discomfort upon removal and
  2. staples become deeply embedded in the tissue.

If effective in securing skin grafts, fibrin glue would directly benefit burn patients by decreasing the number of staples required, and thereby decreasing the number of retained staples. Fibrin sealant is produced from human fibrinogen and human thrombin from pooled plasma that is virally inactivated by a two-stage heating process.

Subjects will serve as their own control. They will have an area of their wound treated with the fibrin sealant and another area treated with the standard of care. Both areas will be compared for hemostasis, skin graft fixation, wound healing, and cosmetic outcome.

Enrollment

25 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Requires skin grafting of an acute or reconstructive burn wound.

Exclusion criteria

  • Active disseminated intravascular coagulation (DIC) or known hypersensitivity to bovine protein.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems